Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9356)
All Articles published online
|
Publishing Process of This Article
|
Mar 7, 2015 (publication date) through Nov 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Zhang YX, Zhou LY, Song ZQ, Zhang JZ, He LH, Ding Y. Primary antibiotic resistance of |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v21/i9/2786.htm |
| Number | Citing Articles |
| 1 |
Chen Chen, Daya Zhang, Shimei Huang, Fan Zeng, Da Li, Xiaodong Zhang, Runxiang Chen, Shiju Chen, Jun Wang, Feihu Bai. Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial. BMC Gastroenterology 2024; 24(1) doi: 10.1186/s12876-024-03225-8
|
| 2 |
Yuehua Gong, Yuan Yuan. Resistance mechanisms ofHelicobacter pyloriand its dual target precise therapy. Critical Reviews in Microbiology 2018; 44(3): 371 doi: 10.1080/1040841X.2017.1418285
|
| 3 |
Lingyun Zhang, Yu Lan, Qi Wang, Yuexia Zhang, Xiaobei Si. Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori. Gastroenterology Research and Practice 2019; 2019: 1 doi: 10.1155/2019/9251879
|
| 4 |
Cai Ling Li, Kai Zhou, Yue Xi Zhang, Bao Jun Suo, Xue Li Tian, Yu Xin Zhang, Xin Lu Ren, Yan Yan Shi, Li Ya Zhou, Zhi Qiang Song. Tailored therapy guided by genotypic resistance of clarithromycin and levofloxacin detected by polymerase chain reaction in the first‐line treatment of Helicobacter pylori infection. Journal of Digestive Diseases 2024; 25(1): 36 doi: 10.1111/1751-2980.13250
|
| 5 |
Liang Wang, Zhengkang Li, Chin Yen Tay, Barry J Marshall, Bing Gu, Yan Tian, Xubo Dai, Hong Du, Qiong Dai, Cui Feng, Qi Fang, Yanjiang Huang, Yizhong Hu, Min He, Guochu Hu, Hui Huang, Qixin Li, Mingbo Liu, Junhong Li, Jinhua Luo, Zhifang Lin, Fen Li, Haitao Liu, Dong Xia, Baohua Man, Jianhong Ma, Shifu Tang, Bofu Tang, Jiliang Wang, Tao Wu, Xiaoling Wang, Handong Wang, Shuchun Wang, Jing Xu, Jiancheng Xu, Qingquan Xie, Rongzhang Xie, Yunxian Ye, Gailing Yuan, Xingcheng Zhu, Shulei Zhao, Wenbi Zou, Liyan Zhang, Bin Zhou. Multicentre, cross-sectional surveillance of Helicobacter pylori prevalence and antibiotic resistance to clarithromycin and levofloxacin in urban China using the string test coupled with quantitative PCR. The Lancet Microbe 2024; 5(6): e512 doi: 10.1016/S2666-5247(24)00027-2
|
| 6 |
Yi Hu, Yin Zhu, Nong-Hua Lu. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00168
|
| 7 |
Majid T. Moghadam, Zahra Chegini, Amin Norouzi, Amin S. Dousari, Aref Shariati. Three-Decade Failure to the Eradication of Refractory Helicobacter pylori Infection and Recent Efforts to Eradicate the Infection. Current Pharmaceutical Biotechnology 2021; 22(7): 945 doi: 10.2174/1389201021666200807110849
|
| 8 |
Xiao-Jian He, Xiang-Peng Zeng, Chuan-Shen Jiang, Gang Liu, Da-Zhou Li, Wen Wang. Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China. Digestive Diseases and Sciences 2022; 67(1): 208 doi: 10.1007/s10620-021-06856-z
|
| 9 |
Xue Yang, Jin-Xia Wang, Sheng-Xi Han, Cai-Ping Gao. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment. Medicine 2019; 98(7): e14396 doi: 10.1097/MD.0000000000014396
|
| 10 |
Xiaoqiong Tang, Zhonghua Wang, Yalin Shen, Xiaona Song, Mohammed Benghezal, Barry J. Marshall, Hong Tang, Hong Li. Antibiotic resistance patterns of Helicobacter pylori strains isolated from the Tibet Autonomous Region, China. BMC Microbiology 2022; 22(1) doi: 10.1186/s12866-022-02613-y
|
| 11 |
I. Thung, H. Aramin, V. Vavinskaya, S. Gupta, J. Y. Park, S. E. Crowe, M. A. Valasek. Review article: the global emergence ofHelicobacter pyloriantibiotic resistance. Alimentary Pharmacology & Therapeutics 2016; 43(4): 514 doi: 10.1111/apt.13497
|
| 12 |
Cheng Shen, Changping Li, Muhan Lv, Xiaosong Dai, Caiping Gao, Liangping Li, Qin Zhang, Wen Pan, Chao Liu, Sijing Han, Yang Zhang, Shunbin Ding, Hong Deng, Yong Yao, Jianyu Xu, Mingyong Wei, Haiyan Shi, Peijie Yuan, Xiaoyan Yang, Yi Jian, Jing Shan, Yan Liu, Zonghua Chen, Xuejie Deng, Fei Liu, Lijuan Deng, Xianfei Zhong, Hong Li, Shaoya He, Li Chen, Gang Liu, Hairong Xu, Yuquan Zhong, Hua Shi, Jiangang Ren.
The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for
H. pylori
infection in Sichuan areas
. Annals of Medicine 2022; 54(1): 426 doi: 10.1080/07853890.2022.2031269
|
| 13 |
Hidekazu Suzuki, Hideki Mori. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. Journal of Gastroenterology 2018; 53(3): 354 doi: 10.1007/s00535-017-1407-1
|
| 14 |
Zong-Dan Jiang, Bang-Shun He, Zhen-Yu Zhang, Shu-Kui Wang, Dan Ran, Zhi-Bing Wang. Analysis of the Primary and Post-Treatment Antibiotic Resistance of Helicobacter pylori in the Nanjing Area. Current Pharmaceutical Biotechnology 2021; 22(5): 682 doi: 10.2174/1389201021666200722162613
|
| 15 |
Si‐Yu Li, Jiang Li, Xin‐Hong Dong, Gui‐Gen Teng, Wei Zhang, Hong Cheng, Wen Gao, Yun Dai, Xiao‐He Zhang, Wei‐Hong Wang. The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing. Helicobacter 2021; 26(4) doi: 10.1111/hel.12804
|
| 16 |
Chuan Han, Zhen Ni, Ting Yuan, Jian Zhang, Chan Wang, Xin Wang, Han Bing Ning, Jie Liu, Nina Sun, Cai Fang Liu, Miao Shi, Wen Quan Lu, Yong Quan Shi. Influence of serum vitamin D level on Helicobacter pylori eradication: A multi‐center, observational, prospective and cohort study. Journal of Digestive Diseases 2019; 20(8): 421 doi: 10.1111/1751-2980.12793
|
| 17 |
Amir Hossein Miri, Mojtaba Kamankesh, Mazda Rad-Malekshahi, Abbas Yadegar, Maryam Banar, Michael R. Hamblin, Ismaeil Haririan, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali. Factors associated with treatment failure, and possible applications of probiotic bacteria in the arsenal againstHelicobacter pylori. Expert Review of Anti-infective Therapy 2023; 21(6): 617 doi: 10.1080/14787210.2023.2203382
|
| 18 |
Gebremicheal Gebreslassie Kasahun, Gebre Teklemariam Demoz, Desilu Mahari Desta. <p>Primary Resistance Pattern of <em>Helicobacter pylori</em> to Antibiotics in Adult Population: A Systematic Review</p>. Infection and Drug Resistance 2020; : 1567 doi: 10.2147/IDR.S250200
|
| 19 |
Tian-Lian Yan, Jian-Guo Gao, Jing-Hua Wang, Dan Chen, Chao Lu, Cheng-Fu Xu. Current status of <i>Helicobacter pylori</i> eradication and risk factors for eradication failure. World Journal of Gastroenterology 2020; 26(32): 4846-4856 doi: 10.3748/wjg.v26.i32.4846
|
| 20 |
Xiaoli Shu, Guofeng Yin, Mingnan Liu, Kerong Peng, Hong Zhao, Mizu Jiang. Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China. Helicobacter 2018; 23(3) doi: 10.1111/hel.12481
|
| 21 |
Yao Chen, Qingyi Liu, Fulian Hu, Jizheng Ma. Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases. MicrobiologyOpen 2020; 9(11) doi: 10.1002/mbo3.1120
|
| 22 |
ShaoWei Han, ZiJie Deng, KaShing Cheung, Tao Lyu, PuiLing Chan, Ying Li, Li Ni, XiaPeng Luo, Kuan Li. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02872-7
|
| 23 |
Hau-Ming Jan, Yi-Chi Chen, Tsai-Chen Yang, Lih-Lih Ong, Chia-Chen Chang, Sasikala Muthusamy, Andualem Bahiru Abera, Ming-Shiang Wu, Jacquelyn Gervay-Hague, Kwok-Kong Tony Mong, Chun-Hung Lin. Cholesteryl α-D-glucoside 6-acyltransferase enhances the adhesion of Helicobacter pylori to gastric epithelium. Communications Biology 2020; 3(1) doi: 10.1038/s42003-020-0855-y
|
| 24 |
Yu-Ming Ding, Yue-Yue Li. Can the optimal treatment duration be determined in bismuth-containing therapies for Helicobacter pylori eradication?. Clinical and Experimental Medicine 2023; 23(7): 4037 doi: 10.1007/s10238-023-01099-w
|
| 25 |
Alessia Savoldi, Elena Carrara, David Y. Graham, Michela Conti, Evelina Tacconelli. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155(5): 1372 doi: 10.1053/j.gastro.2018.07.007
|
| 26 |
Cai Ping Gao, Zhou Zhou, Jia Zhen Wang, Sheng Xi Han, Liang Ping Li, Hong Lu. Efficacy and safety of high‐dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta‐analysis. Journal of Digestive Diseases 2016; 17(12): 811 doi: 10.1111/1751-2980.12432
|
| 27 |
Xiao-Jian He, Xiang-Peng Zeng, Chuan-Shen Jiang, Gang Liu, Da-Zhou Li, Wen Wang. Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial. Arab Journal of Gastroenterology 2021; 22(1): 47 doi: 10.1016/j.ajg.2020.09.005
|
| 28 |
Jia‐Lun Guan, Ying‐Ying Han, Mu‐Ru Wang, Su‐Hong Xia, Ji‐Yan Li, Ming‐Yu Zhang, Kai Zhao, Li‐Na Feng, Yu Zhang, Ruo‐Nan Dong, Jia‐Zhi Liao, Pei‐Yuan Li. Impact of body size on efficacy of high‐dose dual therapy for Helicobacter pylori eradication. Helicobacter 2023; 28(2) doi: 10.1111/hel.12953
|
| 29 |
Meng-Shu Hsieh, Fu-Chen Kuo, Meng-Chieh Wu, Jiunn-Wei Wang, Chung-Jung Liu, Neng-Sheng Chu, Pei-Yun Tsai, Ping-I Hsu, I-Chen Wu, Jeng-Yih Wu, Deng-Chyang Wu, Fang-Jung Yu, Chao-Hung Kuo. Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. Journal of the Formosan Medical Association 2022; 121(8): 1450 doi: 10.1016/j.jfma.2021.10.011
|
| 30 |
Amanullah Abbasi, Shajee Ahmad Siddiqui, Bikha Ram, Jibran Umar Ayub Khan, Khalid Sheikh, Asif Ali, Waseem Raja Memon, Muhammad Rehan, Muhammad Zia ul Haq, Naresh Kumar Seetlani, Tayyab S Akhter, Masood Khoso, Asif Javed, Riaz Hussain Khokhar, Zaheer Hussain Memon, Wajid Akbar, M Naeem, Samiullah Shaikh, Abbas Khan Khattak, A. Qayoom Memon, Shaheen Bhatty, Omar Sultan, Idress Shani, Neeta Maheshwary. Real-World Evidence to Evaluate the Efficacy and Safety of Vonoprazan in Gastrointestinal Disorders in the Pakistani Population. Cureus 2023; doi: 10.7759/cureus.48994
|
| 31 |
Jinnan Chen, Puheng Li, Yu Huang, Yixian Guo, Zhaohui Ding, Hong Lu. Primary Antibiotic Resistance of Helicobacter pylori in Different Regions of China: A Systematic Review and Meta-Analysis. Pathogens 2022; 11(7): 786 doi: 10.3390/pathogens11070786
|
| 32 |
Ling Deng, Xiao-Yi He, Bin Tang, Yang Xiang, Juan-Juan Yue. An improved quantitative real-time polymerase chain reaction technology for Helicobacter pylori detection in stomach tissue and its application value in clinical precision testing. BMC Biotechnology 2020; 20(1) doi: 10.1186/s12896-020-00624-z
|
| 33 |
Takuji Gotoda, Chika Kusano, Sho Suzuki, Toshiki Horii, Ryoji Ichijima, Hisatomo Ikehara. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. Journal of Gastroenterology 2020; 55(10): 969 doi: 10.1007/s00535-020-01709-4
|
| 34 |
Mengheng Mi, Fangcao Wu, Jian Zhu, Fang Liu, Guzhen Cui, Xueqing Wen, Yue Hu, Zhaohui Deng, Xiaojuan Wu, Zhengrong Zhang, Tingna Qi, Zhenghong Chen. Heterogeneity of Helicobacter pylori Strains Isolated from Patients with Gastric Disorders in Guiyang, China. Infection and Drug Resistance 2021; : 535 doi: 10.2147/IDR.S287631
|
| 35 |
Theodore Rokkas, Konstantinos Ekmektzoglou.
Advances in the pharmacological and regulatory management of multidrug resistant
Helicobacter pylori
. Expert Review of Clinical Pharmacology 2023; 16(12): 1229 doi: 10.1080/17512433.2023.2282061
|
| 36 |
Moon-Young Song, Da-Young Lee, Sang-Yong Park, Seul-A Seo, Jeong-Seung Hwang, Soo-Hyeon Heo, Eun-Hee Kim. Steamed Ginger Extract Exerts Anti-inflammatory Effects in Helicobacter pylori-infected Gastric Epithelial Cells through Inhibition of NF-κB. Journal of Cancer Prevention 2021; 26(4): 289 doi: 10.15430/JCP.2021.26.4.289
|
| 37 |
Hidetaka Okubo, Junichi Akiyama, Masao Kobayakawa, Megumi Kawazoe, Saori Mishima, Yusuke Takasaki, Naoyoshi Nagata, Takayuki Shimada, Chizu Yokoi, Shiori Komori, Kana Kimura, Yuya Hisada, Eri Iwata, Kazuhiro Watanabe, Naohiro Yanagisawa, Sho Shiroma, Akira Shimomura, Koki Okahara, Hourin Cho, Naomi Uemura. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. Journal of Gastroenterology 2020; 55(11): 1054 doi: 10.1007/s00535-020-01723-6
|
| 38 |
Tiankuo Yang, Bowen Liu, Junpeng Zhou, Yalin Shen, Xiaona Song, Xiaoqiong Tang, Mohammed Benghezal, Barry James Marshall, Hong Tang, Hong Li. The Inappropriateness of Using Rifampicin E-Test to Predict Rifabutin Resistance in Helicobacter pylori
. The Journal of Infectious Diseases 2022; 226(Supplement_5): S479 doi: 10.1093/infdis/jiac417
|
| 39 |
Jinliang Xie, Jianxiang Peng, Dingwei Liu, Rong Zeng, Jiayu Qiu, Liting Shen, Xiaomin Gong, Dongsheng Liu, Yong Xie. Treatment failure is a key factor in the development of Helicobacter pylori resistance. Helicobacter 2024; 29(3) doi: 10.1111/hel.13091
|
| 40 |
Zhiqiang Song, Baojun Suo, Lingyun Zhang, Liya Zhou. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First‐Line and Second‐Line Regimens for Helicobacter pylori Eradication. Helicobacter 2016; 21(6): 462 doi: 10.1111/hel.12313
|
| 41 |
Lyudmila Boyanova, Rumyana Markovska, José Medeiros, Galina Gergova, Ivan Mitov. Delafloxacin against Helicobacter pylori, a potential option for improving eradication success?. Diagnostic Microbiology and Infectious Disease 2020; 96(4): 114980 doi: 10.1016/j.diagmicrobio.2019.114980
|
| 42 |
Wenwen Gao, Mingliang Zhu, Yanhui Yin, Xiang Zhang, Lu Wang. Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta‐analysis of RCTs. Helicobacter 2023; 28(6) doi: 10.1111/hel.13022
|
| 43 |
Ran Han, Hong Lu, Ming-Wan Jiang, Ke-Wen Tan, Zhong Peng, Jia-Li Hu, Dian-Chun Fang, Chun-Hui Lan, Xiao-Ling Wu. Multicenter Study of Antibiotic Resistance Profile ofH. pyloriand Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/8547686
|
| 44 |
Sho Suzuki, Mitsuru Esaki, Chika Kusano, Hisatomo Ikehara, Takuji Gotoda. Development of <i>Helicobacter pylori</i> treatment: How do we manage antimicrobial resistance?. World Journal of Gastroenterology 2019; 25(16): 1907-1912 doi: 10.3748/wjg.v25.i16.1907
|
| 45 |
Hyun Soo Kim, Hyuk Yoon, Dong Woo Shin, Dong Jun Oh, Mingu Kwon, Yoon Jin Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee. Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Helicobacter pylori Eradication. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2020; 20(3): 218 doi: 10.7704/kjhugr.2020.0021
|
| 46 |
Lingyun ZHANG, Yu LAN, Qi WANG, Xiaobei SI, Yuexia ZHANG. Application of minocycline in patients with Helicobacter pylori infection allergic to penicillin. Food Science and Technology 2022; 42 doi: 10.1590/fst.67121
|
| 47 |
Xiaoqiong Tang, Xiaohong Chen, Yalin Shen, Tiankuo Yang, Renwei Hu, Aleksandra W Debowski, Keith A Stubbs, Mohammed Benghezal, Barry J Marshall, Hong Li, Hong Tang.
Primary Antibiotic Resistance of
Helicobacter Pylori
Among a Chinese Tibetan Population
. Future Microbiology 2020; 15(14): 1353 doi: 10.2217/fmb-2020-0206
|
| 48 |
Marjan Mohammadi, Bahareh Attaran, Reza Malekzadeh, David Y. Graham. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Digestive Diseases and Sciences 2017; 62(8): 1890 doi: 10.1007/s10620-017-4628-5
|
| 49 |
Constanze H. Kubisch, Manfred M. Gross. H. pylori: Antibiotikaresistenzen erschweren die Therapie. MMW - Fortschritte der Medizin 2015; 157(13): 43 doi: 10.1007/s15006-015-3352-3
|
| 50 |
Airu Liu, Yuxin Wang, Yingxiao Song, Yiqi Du. Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection. Saudi Journal of Gastroenterology 2020; 26(2): 78 doi: 10.4103/sjg.SJG_589_19
|
| 51 |
Sankeerth Kumar Motupalli, Terry L. Oroszi. The nexus between Helicobacter pylori infection and anemia—a systematic review. Frontiers in Hematology 2024; 3 doi: 10.3389/frhem.2024.1423494
|
| 52 |
Esteban Isaza-Gómez, Manuel Santiago Ángel-González , Maribel Ocampo-Muñoz, Camilo Andrés Díaz-Quintero, Isabel Cristina Molina-Céspedes, María Antonia Velásquez-Martínez, Pablo Posada-Moreno, Santiago Salazar-Ochoa. Controversias en cirugía: Erradicación del Helicobacter pylori ¿Terapia a todos o según indicaciones usuales?. Revista Colombiana de Cirugía 2020; 35(4): 665 doi: 10.30944/20117582.563
|
| 53 |
Min Ho Lee, Ji Yeong Yang, Yoonjung Cho, Hyun Jun Woo, Hye Jin Kwon, Do Hyun Kim, Min Park, Cheol Moon, Min Ji Yeon, Hyun Woo Kim, Woo-Duck Seo, Sa-Hyun Kim, Jong-Bae Kim. Inhibitory Effects of Menadione on Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation via NF-κB Inhibition. International Journal of Molecular Sciences 2019; 20(5): 1169 doi: 10.3390/ijms20051169
|
| 54 |
Hiroshi Matsumoto, Akiko Shiotani, David Y. Graham. Helicobacter pylori in Human Diseases. Advances in Experimental Medicine and Biology 2019; 1149: 211 doi: 10.1007/5584_2019_367
|
| 55 |
Qiu-Ju Lyu, Qiang-Hong Pu, Xian-Fei Zhong, Jin Zhang. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. BioMed Research International 2019; 2019: 1 doi: 10.1155/2019/9781212
|
| 56 |
Amin Talebi Bezmin Abadi. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017; 8: 123 doi: 10.1016/j.jgar.2016.11.008
|
| 57 |
Shengjuan Hu, Yan Zhou, Yanhong Deng, Yang Bo, Xianmei Chen, Wei Yang, Ruichun Shi, Wei Zhao, Zhanbing Hou, Jianping Hu, Jianguo Liu, Xilong Zhang, Heli Yong, Ping Wang, Fei Li, Hailong Qi, Xiaoyun Wang, Lijuan Jin, Ting Cui, Haijiang Yong, Xue Li, Bin Yang, Yuehua Yu, Bin Ma, Lei Fu, Xuemei Wang, Zhen Ma, Na Tang, Yanjie You, Jianyang Guo, Xiaobing Yu, Li Yao, Ruiping Gao, Yanling Li, Ruijuan Xin, Jianfang Liu, Zhenzi Cao, Hongliang Li, Linke Ma, Shoucheng Ma, Ying Cao, Yuanyuan Tang, Jun Liu, Qian Hao, Xiaofei Li, Xuemei Li, Rui Mu, Min Niu, Xiaoming Su, Hengjun Gao. Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia. Helicobacter 2023; 28(3) doi: 10.1111/hel.12960
|
| 58 |
Zongdan Jiang, Xuetian Qian, Zhi Wang, Yunfan Dong, Yuqin Pan, Zhenyu Zhang, Shukui Wang. Antibiotic resistance of Helicobacter pylori isolated from patients in Nanjing, China: A cross-section study from 2018 to 2021. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.970630
|
| 59 |
Lili Yang, Ao Zou, Huihua Wu, Hai Guo, Fangting Zhang, Bing Zou, Junping Wang, Emily Chia-Yu Su. Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori. BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/6150628
|
| 60 |
Zheyu Wang, Fen Wang. Efficacy and safety comparison of Helicobacter pylori eradication between vonoprazan dual therapy versus triple therapy: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology 2022; 15 doi: 10.1177/17562848221125308
|
| 61 |
Ronita De, Avijit Sarkar, Prachetash Ghosh, Mou Ganguly, Bipul Chandra Karmakar, Dhira Rani Saha, Aniket Halder, Abhijit Chowdhury, Asish K Mukhopadhyay. Antimicrobial activity of ellagic acid against Helicobacter pylori isolates from India and during infections in mice. Journal of Antimicrobial Chemotherapy 2018; 73(6): 1595 doi: 10.1093/jac/dky079
|
| 62 |
Yonglin Li, Rixu Lin, Yin Jin, Shuqing Jin, Bicheng Chen, Xiuling Wu. Genotyping Helicobacter pylori antibiotic resistance and virulence-associated genes in patients with gastric cancer in Wenzhou, China. Arab Journal of Gastroenterology 2021; 22(4): 267 doi: 10.1016/j.ajg.2021.05.017
|
| 63 |
Yongfu Shao, Yifan Lin, Bojun Wang, Min Miao, Guoliang Ye. Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021. Helicobacter 2022; 27(5) doi: 10.1111/hel.12920
|
| 64 |
Yongfu Shao, Rongdan Lu, Yunben Yang, Qiancheng Xu, Bojun Wang, Guoliang Ye. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. Journal of Clinical Laboratory Analysis 2018; 32(4) doi: 10.1002/jcla.22339
|
| 65 |
Ju Yup Lee, Nayoung Kim, Ryoung Hee Nam, Soo In Choi, Jung Won Lee, Dong Ho Lee. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter 2019; 24(6) doi: 10.1111/hel.12660
|
| 66 |
Mohammad Sholeh, Saeed Khoshnood, Taher Azimi, Jasem Mohamadi, Vahab Hassan Kaviar, Marzieh Hashemian, Somayeh Karamollahi, Nourkhoda Sadeghifard, Hedayat Heidarizadeh, Mohsen Heidary, Morteza Saki. The prevalence of clarithromycin-resistant Helicobacter pylori isolates: a systematic review and meta-analysis. PeerJ 2023; 11: e15121 doi: 10.7717/peerj.15121
|
| 67 |
Xiao-Jian He, Xiao-Ling Wang, Xiao-Yan Huang, Da-Zhou Li, Gang Liu, Wen Wang, Dong-Liang Li. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial. Clinics and Research in Hepatology and Gastroenterology 2023; 47(1): 102052 doi: 10.1016/j.clinre.2022.102052
|
| 68 |
Xue‐li Tian, Bao‐jun Suo, Hua Zhang, Hao‐ping Lu, Cai‐ling Li, Yu‐xin Zhang, Xin‐lu Ren, Xing‐yu Yao, Li‐ya Zhou, Zhi‐qiang Song. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first‐line regimen for Helicobacter pylori eradication: A randomized controlled trial. Helicobacter 2023; 28(1) doi: 10.1111/hel.12935
|
| 69 |
Shou Quan Dong, Tikka Prabhjot Singh, Xin Wei, Huang Yao, Hong Ling Wang. Review: A Japanese population‐based meta‐analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?. Helicobacter 2017; 22(6) doi: 10.1111/hel.12438
|
| 70 |
Xiao-Feng Luo, Jian-Hua Jiao, Wen-Yue Zhang, Han-Ming Pu, Bao-Jin Qu, Bing-Ya Yang, Min Hou, Min-Jun Ji. Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of <i>Helicobacter pylori</i>. World Journal of Gastroenterology 2016; 22(25): 5822-5830 doi: 10.3748/wjg.v22.i25.5822
|
| 71 |
Jian Zhang, Chuan Han, Wen Quan Lu, Na Wang, Si Ran Wu, Yong Xi Wang, Jin Ping Ma, Jie Hong Wang, Cheng Hao, Dong Hong Yuan, Na Liu, Yong Quan Shi. A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment. Journal of Digestive Diseases 2020; 21(5): 256 doi: 10.1111/1751-2980.12870
|
| 72 |
Muhammad Miftahussurur, Hafeza Aftab, Pradeep Krishna Shrestha, Rabi Prakash Sharma, Phawinee Subsomwong, Langgeng Agung Waskito, Dalla Doohan, Kartika Afrida Fauzia, Yoshio Yamaoka. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrobial Resistance & Infection Control 2019; 8(1) doi: 10.1186/s13756-019-0482-x
|
| 73 |
Shuhan Qiu, Yu Huang, Jinnan Chen, Yixian Guo, Meixuan Li, Zhaohui Ding, Xiao Liang, Hong Lu. Vonoprazan–Amoxicillin Dual Therapy With Different Amoxicillin Administration Regimens for Helicobacter pylori Treatment: A Randomized Controlled Trial. Helicobacter 2024; 29(4) doi: 10.1111/hel.13118
|
| 74 |
Siya Kong, Keting Huang, Jun Wang, Xiaoyong Wang, Ningmin Yang, Yu Dong, Ya Zhuang, Yini Dang, Guoxin Zhang, Feng Ye. Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study. Gut Pathogens 2020; 12(1) doi: 10.1186/s13099-020-00378-1
|
| 75 |
Ya Wang, Shuang Wu, Le Wang, Youhua Wang, Dongsheng Liu, Yingjun Fu, Yong Xie. The Activity of Liposomal Linolenic Acid Against Helicobacter pylori In Vitro and Its Impact on Human Fecal Bacteria. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.865320
|
| 76 |
Xiao-Jian He, Xiao-Ling Wang, Dong-Jie Sun, Xiao-Yan Huang, Gang Liu, Da-Zhou Li, Hai-Lan Lin, Xiang-Peng Zeng, Dong-Liang Li, Wen Wang. The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848221147763
|
| 77 |
Dan-Ni Liu, Qiu-Yan Wang, Pei-Yuan Li, Dong-Han Wu, Jing Pan, Zheng-Yi Chen, Yan-Qiang Li, Xiang-Yang Han, Cheng Lan, Jing Tang, Yan Tan, Cui-Yi Mo, Wei-Zhong Yang, Jun-Ling Han, Xiao-Xi Huang. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial. Clinics and Research in Hepatology and Gastroenterology 2023; 47(5): 102125 doi: 10.1016/j.clinre.2023.102125
|
| 78 |
Lyudmila Boyanova, Petyo Hadzhiyski, Nayden Kandilarov, Rumyana Markovska, Ivan Mitov. Multidrug resistance inHelicobacter pylori: current state and future directions. Expert Review of Clinical Pharmacology 2019; 12(9): 909 doi: 10.1080/17512433.2019.1654858
|
| 79 |
Tao Liu, Shuang Chai, Mingyang Li, Xu Chen, Yutao Xie, Zehui Zhao, Jingjing Xie, Yunpeng Yu, Feng Gao, Feng Zhu, Lihua Yang. A nanoparticle-based sonodynamic therapy reduces Helicobacter pylori infection in mouse without disrupting gut microbiota. Nature Communications 2024; 15(1) doi: 10.1038/s41467-024-45156-8
|
| 80 |
Wen Zhong Liu, Yong Xie, Hong Lu, Hong Cheng, Zhi Rong Zeng, Li Ya Zhou, Ye Chen, Jiang Bin Wang, Yi Qi Du, Nong Hua Lu. Fifth Chinese National Consensus Report on the management ofHelicobacter pyloriinfection. Helicobacter 2018; 23(2) doi: 10.1111/hel.12475
|
| 81 |
Alba A. Trespalacios-Rangél, William Otero, Azucena Arévalo-Galvis, Raúl A. Poutou-Piñales, Emiko Rimbara, David Y. Graham, Massimiliano Galdiero. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLOS ONE 2016; 11(7): e0160007 doi: 10.1371/journal.pone.0160007
|
| 82 |
Ji Yeong Yang, Jong-Bae Kim, Pyeongjae Lee, Sa-Hyun Kim. Evodiamine Inhibits Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation. International Journal of Molecular Sciences 2021; 22(7): 3385 doi: 10.3390/ijms22073385
|
| 83 |
Yuxiang Wang, Jinran Du, Dayan Zhang, Cong Jin, Jiangpo Chen, Zeyuan Wang, Tonglin Mei, Kaili Fu, Qingzeng Qian, Tieliang Pang. Primary antibiotic resistance in Helicobacter pylori in China: a systematic review and meta-analysis. Journal of Global Antimicrobial Resistance 2023; 34: 30 doi: 10.1016/j.jgar.2023.05.014
|
| 84 |
Bipul Chandra Karmakar, Sangita Paul, Surajit Basak, Manisha Ghosh, Piyali Mukherjee, Rajashree Das, Sujit Chaudhuri, Shanta Dutta, Asish Kumar Mukhopadhyay. Development and evaluation of a simple PCR assay and nested PCR for rapid detection of clarithromycin-resistant Helicobacter pylori from culture and directly from the biopsy samples in India. Gut Pathogens 2023; 15(1) doi: 10.1186/s13099-023-00530-7
|
| 85 |
Bo Ma, Ji Ma, Dong Liu, Ling Guo, Huiling Chen, Jingjin Ding, Wei Liu, Hongquan Zhang. Biochemical and structural characterization of a DNA N6-adenine methyltransferase fromHelicobacter pylori. Oncotarget 2106; 7(27): 40965 doi: 10.18632/oncotarget.9692
|
| 86 |
Dong-Min Yi, Tao-Tao Yang, Shuai-Heng Chao, Ya-Xin Li, Ying-Lei Zhou, Hai-Hui Zhang, Ling Lan, Yu-Wei Zhang, Xue-Mei Wang, Yan-Rui Zhang, Jian Li, Song-Ze Ding. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. Medicine 2019; 98(6): e14408 doi: 10.1097/MD.0000000000014408
|
| 87 |
Yanmeng Wang, Yiling Li, Yuehua Gong, Yuzhen Dong, Jing Sun, Moye Chen. Antibiotic resistance characteristics and risk factors analysis of Helicobacter pylori strains isolated from patients in Liaoning Province, an area in North China. PeerJ 2023; 11: e15268 doi: 10.7717/peerj.15268
|
| 88 |
Fernando Macías‐García, José Llovo‐Taboada, Mario Díaz‐López, Iria Bastón‐Rey, Juan Enrique Domínguez‐Muñoz. High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross‐sectional study in Spain. Helicobacter 2017; 22(6) doi: 10.1111/hel.12440
|
| 89 |
Raluca Ioana Dascălu, Alexandra Bolocan, Dan Nicolae Păduaru, Alexandru Constantinescu, Magda Mihaela Mitache, Anca Daniela Stoica, Octavian Andronic. Multidrug resistance in Helicobacter pylori infection. Frontiers in Microbiology 2023; 14 doi: 10.3389/fmicb.2023.1128497
|
| 90 |
Lei Gu, Shenglan Li, Ying He, Yi Chen, Yanzhi Jiang, Yu Peng, Xiaowei Liu, Huixiang Yang. Bismuth, rabeprazole, amoxicillin, and doxycycline as first‐line Helicobacter pylori therapy in clinical practice: A pilot study. Helicobacter 2019; 24(4) doi: 10.1111/hel.12594
|
| 91 |
Zhi Qiang Song, Li Ya Zhou. Esomeprazole, minocycline, metronidazole and bismuth as first‐line and second‐line regimens for Helicobacter pylori eradication. Journal of Digestive Diseases 2016; 17(4): 260 doi: 10.1111/1751-2980.12334
|
| 92 |
Bekir Kocazeybek, Hrisi Bahar Tokman. Prevalence of Primary Antimicrobial Resistance of H. pylori in Turkey: A Systematic Review. Helicobacter 2016; 21(4): 251 doi: 10.1111/hel.12272
|
| 93 |
Reyhan Caliskan, Hrisi Bahar Tokman, Yusuf Erzin, Suat Saribas, Pelin Yuksel, Bora Kazim Bolek, Ecehan Ozge Sevuk, Mehmet Demirci, Ozge Yılmazli, Ozer Akgul, Fatma Kalayci, Huseyin Cakan, Barik Salih, Kadir Bal, Bekir Kocazeybek. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Revista da Sociedade Brasileira de Medicina Tropical 2015; 48(3): 278 doi: 10.1590/0037-8682-0027-2015
|
| 94 |
D.-S. Liu, Y.-H. Wang, Z.-R. Zeng, Z.-Y. Zhang, H. Lu, J.-M. Xu, Y.-Q. Du, Y. Li, J.-B. Wang, S.-P. Xu, Y. Chen, C.-H. Lan, H. Cheng, M.-D. Jiang, L.-X. Zhang, L.-J. Huo, S.-Y. Chen, G.-X. Zhang, K.-C. Wu, X. Zhu, Y.-X. Chen, Y. Zhu, X. Shu, Y. Xie, N.-H. Lu. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clinical Microbiology and Infection 2018; 24(7): 780.e5 doi: 10.1016/j.cmi.2017.11.010
|
| 95 |
Xinyi Wei, Junfei Zhou, Liping Zeng, Mingming Xu, Chuntao Che, Jin’ao Duan, Hui Yan, Hongkai Bi, Ming Zhao. Highly oxygenated dihydrostilbenoids and flavones from the aerial part of Glycyrrhiza uralensis and their antimicrobial activities. Science of Traditional Chinese Medicine 2024; doi: 10.1097/st9.0000000000000048
|
| 96 |
De-Bin Zhu, Jin-Ming Wu. Risk factors for treatment ineffectiveness in patients with H. pylori infection undergoing eradication treatment according to drug susceptibility testing results. World Chinese Journal of Digestology 2019; 27(8): 509 doi: 10.11569/wcjd.v27.i8.509
|
| 97 |
Yi Hu, Yin Zhu, Nong-hua Lu. Primary Antibiotic Resistance of Helicobacter pylori in China. Digestive Diseases and Sciences 2017; 62(5): 1146 doi: 10.1007/s10620-017-4536-8
|
| 98 |
Hye Jin Kwon, Min Ho Lee, Hyun Woo Kim, Ji Yeong Yang, Hyun Jun Woo, Min Park, Cheol Moon, Sa-Hyun Kim, Jong-Bae Kim. Riboflavin Inhibits Growth of Helicobacter pylori by Down-regulation of polA and dnaB Genes. Biomedical Science Letters 2020; 26(4): 288 doi: 10.15616/BSL.2020.26.4.288
|